Project Grant R01AI190169
- This federal Project Grant award for $3,364,935.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to functionally and mechanistically characterize genetic factors that contribute to the development of systemic lupus erythematosus (SLE). The research aims to elucidate the role of autophagy, a cellular process, in the pathogenesis of SLE, particularly in immune cells and...
- This $793,093 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define the regulatory landscape of systemic lupus erythematosus (SLE) and its cardiovascular disease (CVD) comorbidity. The grantee, Oklahoma Medical Research Foundation, will conduct systematic, high-throughput studies in macrophages derived from induced pluripotent stem cells to identify genetic variants that disrupt regulatory...
- This federal Project Grant award in the amount of $700,000.00, provided by the National Institute of General Medical Sciences (CFDA 93.859 - Biomedical Research and Research Training program), supports research to investigate the role of the ARID3A protein in systemic lupus erythematosus (SLE) and other autoimmune diseases. The award will fund a research project at the University of Oklahoma Health Sciences Center to: 1) define genes and epigenetic regions directly regulated by ARID3A expression...
- This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine the therapeutic potential of CpG-B oligonucleotides (ODNs) for the management of systemic lupus erythematosus (SLE). The $132,930 award, active from January 2025 to July 2028, will support in vitro and in vivo studies using MRL/lpr and humanized mouse models to investigate how CpG-B ODNs, which mimic bacterial...
- This federal Project Grant award of $2,989,958 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Thomas Jefferson University's Sidney Kimmel Medical College. The grant supports research to delineate the mechanisms by which pyrimidine synthesis promotes systemic autoimmunity in systemic lupus erythematosus (SLE). The research aims to improve understanding of the role of pyrimidine...
- This $558,045 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate how the enzyme protein phosphatase 2A (PP2A) controls the function of T cells and contributes to the development of systemic lupus erythematosus (SLE). The research aims to determine how PP2A regulates metabolic enzymes involved in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774.00 to the University of Alabama at Birmingham (UAB) over a 5-year period starting November 19, 2024. The award supports research to investigate the role of the aryl hydrocarbon receptor (AhR) pathway in regulating the development of T-bet+ B cells, which are implicated in the pathogenesis of systemic lupus...
- The federal Project Grant award of $999,999.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Oklahoma Medical Research Foundation (OMRF) to conduct research on the impact of IFIH1 during systemic lupus erythematosus. The award period is from May 1, 2025 to April 30, 2028. OMRF, a non-profit biomedical research institute, will leverage its extensive expertise in autoimmune disease research, genomics, and animal...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $715,957.00 to Northwestern University to conduct research on the mechanisms by which type I interferon cytokines support the production and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The research aims to elucidate the molecular pathways...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate the cellular and molecular mechanisms by which a specific genetic variant of the IFIH1 gene (IFIH1R) promotes the development of systemic lupus erythematosus (SLE). The $2,430,679 award, with a performance period from September 2025 to August 2029, will be used by the Oklahoma Medical Research Foundation (OMRF) to: 1) examine how the IFIH1R variant enhances inflammation, 2) determine if IFIH1R promotes SLE pathogenesis in a murine model, and 3) evaluate how the IFIH1R variant alters the interferon signature and immune cell functions in healthy individuals and SLE patients. The goal of this research is to gain a better understanding of the mechanisms driving inflammation and SLE pathogenesis, which could help stratify patients and inform therapeutic strategies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.4m | 9/3/25 |